We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

Cardiovascular · 7 min read

Cardiovascular risk in midlife women: what changes and what to do

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published · Updated

Heart disease — not breast cancer — is the leading cause of death in women. Menopause is the inflection point.

Cardiovascular disease causes more deaths in women than all cancers combined. Risk is low in the reproductive years and accelerates sharply after menopause as estrogen-mediated vascular protection fades.

What changes at menopause

  • LDL cholesterol typically rises
  • Visceral fat increases — itself an independent risk factor
  • Blood pressure often drifts upward
  • Insulin sensitivity declines

What to do

  • Annual lipid panel and blood pressure
  • Resistance and aerobic training
  • A Mediterranean-pattern diet with adequate protein
  • Sleep protection
  • HRT, when indicated and started in the early postmenopausal window — does not appear to increase, and may reduce, coronary risk

Sources

Medically reviewed by Kindr Health Clinical Team
Last updated: May 10, 2026

More on long-term midlife health

Continue across the Kindr entity graph

Related evidence, peptides, and clinical tools on the same topic.

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Keep reading

Research

Hot flashes and your relationship: what partners miss, and how to start the treatment conversation

In a U.S. survey of 253 couples, 78.7% of the women, all with bothersome hot flashes, said they had never been treated for them. Here's what partners often miss, a visit-prep script, and hormonal and nonhormonal options to discuss.

Research

FDA requires GLP-1 label updates for a potential NAION eye risk: what it means

FDA is requiring GLP-1 label updates for a potential increased risk of NAION—sudden, painless vision loss in one eye. Here's what patients should know.

Research

Non-Hormonal Hot Flash Treatment: Lynkuet vs Veozah

Veozah and Lynkuet are two newer FDA-approved nonhormonal options for hot flashes. How they differ, key risks, and what to ask your clinician. Educational only.

Explore your next step

Kindr Care is being updated, and the exact clinical process will depend on the current care pathway.

Explore care options →